Overview

Efficacy and Safety of Losartan in Children With Ig A Nephropathy

Status:
Completed
Trial end date:
2017-04-01
Target enrollment:
Participant gender:
Summary
The investigators hypothesize that using Losartan would help decrease proteinuria in controlling proteinuria in children with immunoglobulin A nephropathy.
Phase:
Phase 3
Details
Lead Sponsor:
Seoul National University Hospital
Collaborator:
Ministry of Food and Drug Safety, Korea
Treatments:
Losartan